目錄:MedChemExpress LLC>>生化試劑>> Rogaratinib | MCE
CAS | 1443530-05-9 | 純度 | 99.86% |
---|---|---|---|
分子量 | 466.56 | 分子式 | C??H??N?O?S |
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 1 mg |
貨號 | HY-100019 | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。
CAS No. : 1443530-05-9
產(chǎn)品活性:Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor.
研究領(lǐng)域:Protein Tyrosine Kinase/RTK
作用靶點(diǎn):FGFR
In Vitro: Of the 24 cell lines, 2 FGFR1-amplified lung cancer (LC) cell lines, H1581 and DMS114, show extreme sensitivity to Rogaratinib (BAY1163877) (GI50 values ranging from 36 to 244?nM). Treatment with Rogaratinib results in a significant decrease in colonies formed by H1581P cells, but not by H1581AR and BR cells. Ectopic expression of Met significantly induces resistance to Rogaratinib in MTT assays. Met overexpression induces activation of downstream extracellular signal-regulated kinase 1/2 (ERK1/2) and AKT, which cannot be abrogated by Rogaratinib treatment.
相關(guān)產(chǎn)品:Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Drug Repurposing Compound Library | Reprogramming Compound Library | Anti-Lung Cancer Compound Library | Angiogenesis-Related Compound Library | Targeted Diversity Library | Anti-Liver Cancer Compound Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | FGFR4-IN-12 | FGFR2-IN-2 | Multi-kinase-IN-2 | FGFR1 inhibitor-6 | FGFR4-IN-4 | FGFR3-IN-3 | FGFR-IN-7 | PP58 | FGFR4-IN-10 | Vosoritide acetate | ODM-203 | ENMD-2076 Tartrate | R1530 | Gunagratinib | Ponatinib hydrochloride | Nintedanib | Heparan Sulfate | CPL304110 | Futibatinib | Trafermin | Roblitinib | PD173074 | FGFR-IN-2 | Lucitanib | Masitinib | Nintedanib-13C,d3 | Zoligratinib | BLU9931 | MAX-40279 hemifumarate | Pazopanib-13C,d3 (hydrochloride)
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標(biāo)記物 | 寡核苷酸 | 抗體 | 點(diǎn)擊化學(xué)
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動(dòng)劑涉及各熱門信號通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項(xiàng)目;
• 提供虛擬篩選,離子通道篩選,代謝組學(xué)分析檢測分析,藥物篩選等專業(yè)技術(shù)服務(wù);
• 設(shè)有專業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國客戶實(shí)驗(yàn)驗(yàn)證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團(tuán)隊(duì)跟蹤最新的制藥及生命科學(xué)研究進(jìn)展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機(jī)構(gòu)建立了長期的合作。
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)